Tuesday, September 09, 2008 12:31:51 AM
Recent BOLT News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 09:43:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:14:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:06:42 PM
- Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/21/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 06:29:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 06:27:52 PM
- Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/13/2024 02:41:27 AM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 06:09:39 PM
- Pacira Appoints Frank D. Lee as Chief Executive Officer • GlobeNewswire Inc. • 12/21/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 06:40:19 PM
- Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu® • GlobeNewswire Inc. • 12/05/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:08:11 PM
- Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/07/2023 12:00:00 PM
- Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress • GlobeNewswire Inc. • 10/23/2023 02:30:00 PM
- Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting • GlobeNewswire Inc. • 10/18/2023 11:00:00 AM
- Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers • GlobeNewswire Inc. • 10/17/2023 11:00:00 AM
- Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023 • GlobeNewswire Inc. • 10/16/2023 11:00:00 AM
- Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers • GlobeNewswire Inc. • 09/28/2023 11:00:00 AM
- Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042 • GlobeNewswire Inc. • 09/12/2023 12:05:25 PM
- Bolt Biotherapeutics to Participate in September Investor Conferences • GlobeNewswire Inc. • 09/05/2023 08:15:00 PM
- Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/07/2023 08:10:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM